MétaCan
Menu
Back to cohort
Record W4412143798 · doi:10.1002/brb3.70661

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review

2025· review· en· W4412143798 on OpenAlexaff
Shakila Meshkat, Corinna Di Luciano, Alyssa Swiderski, Guoqiang Li, Reinhard Janssen Aguilar, Benjamin T. Dunkley, Amy C. Reichelt, Yanbo Zhang, Andrew J. Greenshaw, Eric Vermetten, Satya Ranjan Dash, Sri Mahavir Agarwal, Jennifer Swainson, Venkat Bhat

Bibliographic record

VenueBrain and Behavior · 2025
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsCentre for Addiction and Mental HealthRoyal Ottawa Mental Health CentreUniversity of OttawaWomen and Children’s Health Research InstituteUniversity of AlbertaSt. Michael's HospitalWestern UniversityMental Health Research CanadaHospital for Sick ChildrenToronto General HospitalUniversity of Toronto
Fundersnot available
KeywordsGlucagon-like peptide-1MedicineExenatidePsychiatryPsychologyEndocrinologyDiabetes mellitusType 2 diabetes

Abstract

fetched live from OpenAlex

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as potential therapeutic options for psychiatric symptoms due to their effects on mood and behavior. However, their use has been primarily for metabolic diseases, and limited research has evaluated their psychiatric efficacy. This systematic review examined the impact of GLP-1 RAs on psychiatric symptoms, categorizing studies based on whether psychiatric outcomes were primary or secondary. METHODS: A comprehensive search through OVID databases from inception to November 2024 identified 26 studies (n = 3020), with 5 studies evaluating psychiatric symptoms as primary outcomes (e.g., substance use disorders) and 21 studies assessing secondary outcomes across various conditions. Additionally, 10 registered clinical trials were identified. RESULTS: Among the five studies targeting primary outcomes, exenatide and dulaglutide were investigated in cocaine use disorder, alcohol use disorder, and nicotine dependence. Exenatide 2 mg once-weekly demonstrated reductions in cocaine craving in two cases over 6 weeks in a case series study. However, mixed results were reported across studies, including no significant changes in a separate case series (n = 12, p = 0.46). Dulaglutide 1.5 mg weekly did not significantly affect smoking abstinence (RR = 0.87, p = 0.25) but reduced alcohol consumption by 29% in a secondary analysis. For studies assessing secondary outcomes, GLP-1 RAs showed variable effects. In mood disorders, liraglutide 1.8 mg/day significantly improved depression and anhedonia. In Type 2 diabetes, semaglutide improved diabetes-related quality of life (Cohen' and anxiety (Cohen's d = 0.48) compared to dulaglutide. Exenatide studies reported mixed results, with one randomized controlled trial (RCT) showing significant reductions in Beck's Depression Inventory (BDI) scores (Δ = -5.2). A total of nine RCTs were included in this review and the risk of bias was assessed using the JBI Critical Appraisal Checklist for RCTs. All included RCTs met the majority of criteria, indicating moderate-to-high methodological quality. Of the included RCTs, three reported a statistically significant effect on the primary psychiatric outcome, whereas six reported no significant effect. CONCLUSION: GLP-1 RAs showed mixed and inconclusive effects on psychiatric symptoms. Although some studies suggested potential benefits, others reported null findings. Given the variability across trials, further research is needed to clarify their therapeutic potential.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.021
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.008
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.021
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0080.008
Bibliometrics0.0060.006
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0020.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.340
Teacher spread0.319 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBrain and BehaviorSame topicDiabetes Treatment and ManagementFrench-language works237,207